What's Happening?
Anbogen Therapeutics Inc., a clinical-stage precision oncology company, has entered into a Collaborative Research Agreement (CRA) with the Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo. This
partnership aims to evaluate ABT-301 (Imofinostat), Anbogen's selective Class I histone deacetylase inhibitor (HDACi), across various solid tumor types, including osteosarcoma, melanoma, soft tissue sarcoma, and bladder cancers. The research will utilize established veterinary oncology models, particularly focusing on naturally occurring cancers in dogs, which are recognized for their clinical and molecular similarities to human cancers. Canine osteosarcoma is highlighted as a key model due to its biological and clinical resemblance to human osteosarcoma. The collaboration seeks to generate scientific evidence to support the expansion of ABT-301's human clinical indications and optimize combination strategies for future clinical trials. The research team at The University of Tokyo, led by Lecturer Daiki Kato, Professor Takayuki Nakagawa, and Professor Manabu Mochizuki, brings extensive expertise in translational oncology and operates a comprehensive comparative oncology platform.
Why It's Important?
This collaboration is significant for accelerating human clinical development in oncology by leveraging comparative oncology. Naturally occurring cancers in dogs offer a unique opportunity to study therapeutic strategies at disease stages that are often difficult to assess in early human clinical development. The insights gained from canine models can directly inform human clinical trial design, patient selection strategies, and regulatory submissions. ABT-301, currently in Phase I/II clinical trials for metastatic colorectal cancer, is designed to modulate the tumor immune microenvironment and sensitize tumors to immune checkpoint inhibition. This mechanism suggests broad applicability across immunotherapy-resistant solid tumors. The use of canine models, which faithfully recapitulate key biological, immunological, and clinical features of human cancers, provides a robust platform for generating cross-species translational evidence. This approach could lead to more effective and targeted cancer treatments, potentially benefiting a wider range of cancer patients by identifying new indications and optimal combination therapies for ABT-301.
What's Next?
The collaboration will involve evaluating ABT-301 as a monotherapy and in combination with other agents using The University of Tokyo's proprietary preclinical models. Comprehensive mechanistic analyses will be conducted to elucidate ABT-301's mechanism of action and identify molecular backgrounds predictive of response. The findings from this research will directly inform the selection of indications and the design of combination regimens for future human clinical trials. The goal is to generate scientifically robust translational data to support future indication expansion and clinical development decisions for ABT-301. This strategic partnership is expected to systematically assess ABT-301 across a broad range of difficult-to-treat solid tumors, extending its clinical potential beyond its current colorectal cancer program. The resulting evidence will be crucial for designing and supporting the expansion of ongoing human clinical development into new indications.
Beyond the Headlines
The use of comparative oncology, particularly with canine models, represents a deeper shift in cancer research methodology. It acknowledges the limitations of traditional mouse models in replicating the natural complexity of drug resistance, metastasis, and tumor-host immune interactions. By studying naturally occurring cancers in dogs, which develop spontaneously under environmental and lifestyle conditions shared with humans, researchers can gain a more realistic understanding of disease biology. This approach not only accelerates drug development but also raises ethical considerations regarding animal welfare in research, emphasizing the importance of humane treatment and the potential for direct benefits to veterinary medicine. The success of this collaboration could pave the way for increased integration of comparative oncology into the broader pharmaceutical development landscape, fostering a more holistic and translational approach to cancer treatment that benefits both human and animal health.
